GDF15 and COVID-19: Taken together, these findings show that along with significant changes in inflammatory and cardiovascular biomarkers during SARS-CoV-2 infection, GDF-15 may represent a clinically useful risk stratification tool that provides important pathophysiological insights and prognostic information in CKD patients hospitalized with COVID-19.